ARTICLE | Company News
University of Texas MD Anderson Cancer Center, Astellas deal
April 6, 2015 7:00 AM UTC
MD Anderson granted Astellas an option to license exclusive, worldwide rights to develop h8F4 after a Phase Ib trial to treat acute myelogenous leukemia (AML) conducted by MD Anderson. The compound i...